Home > Back to Publisher > Report Information

MarketVIEW: H1N1 vaccine (Global demand model)

VacZine Analytics
September 1, 2009
20 Pages - SKU: VZAN2468882

Abstract Table of Contents Related Reports

H1N1 or “Swine flu” is a pandemic strain of the influenza A virus which emerged in April 2009. In its latest update (number 69), the World Health Organisation (WHO) stated there has been around 375,000 confirmed cases and 4500 reported deaths globally due to the virus.

Vaccine manufacturers are now actively producing H1N1 pandemic specific vaccines which are now reaching regulatory approval in the US and EU. The US ACIP committee has recently published recommendations regarding initial target groups for vaccination.

Prioritization will be especially relevant if initial supplies are limited. Using currently available information regarding the expected profile, predicted allocation of H1N1 specific vaccine and predictions of pandemic severity, VacZine Analytics has modelled theoretical global vaccine demand. The provided model and presentation also give indications of potential cumulative revenue/markets share (for vaccine manufacturers) using adjustable inputs of vaccine pricing, penetration and number of doses per course.

Please note:this is delivered as a zip file.

NOTE: This product contains a forecast model and summary presentation (15-20 slides)
Contents - Summary presentation (MS Powerpoint-based): Markets included in model; Broad assumptions for H1N1 vaccine: theoretical demand (US); Broad assumptions for H1N1 vaccine: theoretical demand (EU); Major model assumptions (global); Estimated numbers in US vaccination Tiers; Vaccine demand model assumptions - Western Markets; Vaccine demand model assumptions - Emerging Markets; Theoretical predicated H1N1 vaccine demand per quarter (000 doses); Cumulative revenue potential (Q3 2009 - Q4 2012); Statements on required/planned vaccine volume per country (Western); Statements on required/planned vaccine volume per country (Emerging); Other statements on required/planned vaccine volume; Company statements on required/planned vaccine volume (Medimmune); Company statements on required/planned vaccine volume (GSK Biologicals); Company statements on required/planned vaccine volume (Sanofi Pasteur); Company statements on required/planned vaccine volume (Novartis Vaccines); WHO tenders; About VacZine Analytics; Disclaimer
Contents - Vaccine demand model (MS Excel-based): Title sheet; Charts (Western); Cumulative revenue (company); Value summary (Western); Value summary (Emerging); Market share summary (Western); Market share summary (Emerging); Volume summary (Western); Volume summary (Emerging); H1N1 North America; US priority subsets; US initial target groups; Canada priority subsets; Canada initial target groups; H1N1 EU; UK priority subsets; UK initial target groups; France priority subsets; France initial target groups; Germany priority subsets; Germany initial target groups; Italy priority subsets; Italy initial target groups; Spain priority subsets; Spain initial target groups; Other EU priority subsets; Other EU target groups; US priority subsets; US initial target groups; H1N1 (Japan + Australia); Japan priority subsets; Japan initial target groups; Australia priority subsets; Australia initial target groups; H1N1 (Major Asia); India priority subsets; India initial target groups; China priority subsets; China initial target groups; Russia priority subsets; Russia initial target groups; H1N1 (Latin America - LATAM); Brazil priority subsets; Brazil target groups; Mexico priority subsets; Mexico initial target groups; Argentina priority subsets; Argentina initial target groups; Population database; 6 mos - 24 yrs; H5N1 material; US H5N1 tier definitions; US H5N1 tier subpriority; US Extrapolation; Source material; Back page; About VacZine Analytics; Disclaimer

MarketVIEW: H1N1 vaccine (Global demand model)

Share this report

Other tasks

Research Assistance

Related Markets

Pandemic Vaccines Reports

Free Alert Me service